CANCER EPIDEMIOLOGY

Revised: 24 June 2022



Effect of a physical activity intervention on lower body bone health in childhood cancer survivors: A randomized controlled trial (SURfit)

Ruedi Jung ¹ Simeon J. Zürcher ² Christina Schindera ^{3,4} Prisca Eser ⁵	
Christian Meier ⁶ 💿 Anna Schai ¹ Julia Braun ¹ 💿 Wei Hai Deng ⁷ 💿	
Helge Hebestreit ⁸ 💿 Cornelia Neuhaus ⁹ 💿 Jonathan Schaeff ¹⁰	
Corina S. Rueegg ⁷ 💿 📔 Nicolas X. von der Weid ³ 💿 📔 Susi Kriemler ¹ 💿	

¹Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

²Center for Psychiatric Rehabilitation, Universitäre Psychiatrische Dienste Bern (UPD) and University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland

³Department of Pediatric Hematology and Oncology, University Children's Hospital Basel (UKBB) and University of Basel, Basel, Switzerland

⁴Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

⁵University Clinic of Cardiology, Preventive Cardiology and Sports Medicine, Inselspital, University Hospital Bern, Bern, Switzerland

⁶Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland

⁷Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway

⁸Paediatric Department, University Hospital, Julius-Maximilians University, Würzburg, Germany

⁹Therapy Department, University Children's Hospital Basel (UKBB) and University of Basel, Basel, Switzerland

¹⁰Paediatric Department, University Hospital Augsburg, Augsburg, Germany

Correspondence

Susi Kriemler, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland. Email: susi.kriemlerwiget@uzh.ch

Funding information

European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND), Grant/Award Number: 609020; Fond'Action contre le Cancer; Fondation Recherche sur le Cancer de l'Enfant (FORCE); Gedächtnis-Stiftung Susy Rückert zur Krebsbekämpfung; South-Eastern Norway Regional Health Authority, Grant/Award Number: 2019039; Stiftung für krebskranke Kinder, Regio Basiliensis; Stiftung Henriette & Hans-Rudolf Dubach-Bucher; Stiftung Krebs-Hilfe Zürich; Stiftung zur Krebsbekämpfung; Swiss Cancer

Abstract

It remains controversial whether physical activity promotes bone health in childhood cancer survivors (CCS). We aimed to assess the effect of a one-year general exercise intervention on lower body bone parameters of CCS. CCS \geq 16 years at enrollment, <16 years at diagnosis and \geq 5 years in remission were identified from the national Childhood Cancer Registry. Participants randomized to the intervention group were asked to perform an additional \geq 2.5 hours of intense physical activity/week, controls continued exercise as usual. Bone health was assessed as a secondary trial endpoint at baseline and after 12-months. We measured tibia bone mineral density (BMD) and morphology by peripheral quantitative computed tomography and lumbar spine, hip and femoral neck BMD by dual-energy x-ray absorptiometry. We performed intention-to-treat, per protocol, and an explorative subgroup analyses looking at low

Abbreviations: BMD, bone mineral density (mg/cm³ or g/cm²); CCS, childhood cancer survivor(s); CPET, cardiopulmonary exercise test; DXA, dual-energy x-ray absorptiometry; ITT, intention-to-treat analysis; PA, physical activity; pQCT, peripheral quantitative computed tomography; RCT, randomized controlled trial.

Ruedi Jung, Simeon J. Zürcher, Corina S. Rueegg, Nicolas X. von der Weid and Susi Kriemler contributed equally to this publication.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. *International Journal of Cancer* published by John Wiley & Sons Ltd on behalf of UICC.

League, Grant/Award Number: KLS-3175-02-2013; Taecker-Stiftung für Krebsforschung



BMD using multiple linear regressions. One hundred fifty-one survivors (44% females, 7.5 ± 4.9 years at diagnosis, 30.4 ± 8.6 years at baseline) were included. Intention-to-treat analysis revealed no differences in changes between the intervention and control group. Per protocol analyses showed evidence for an improvement in femoral neck and trabecular BMD between 1.5% and 1.8% more in participants being compliant with the exercise program. Trabecular BMD increased 2.8% more in survivors of the intervention group with BMD z-score ≤ -1 compared to those starting at z-score ≥ -1 . A nonstandardized personalized exercise programs might not be specific enough to promote bone health in CCS, although those compliant and those most in need may benefit. Future trials should include bone stimulating exercise programs targeting risk groups with reduced bone health and motivational features to maximize compliance.

KEYWORDS

bone health, bone mineral density, childhood cancer survivors, exercise, physical activity

What's new?

Survivors of childhood cancer have increased vulnerability later in life to decreased bone mineral density (BMD) and fractures. Here, the authors tested whether a one-year exercise program could help improve lower-body bone health among 151 cancer survivors, age 16 and up. Those randomized to the exercise group performed an additional 2.5 hours of intense physical activity each week, while those in the control group continued their usual exercise habits. Bone mineral density was measured in the lumbar spine, hip, femoral neck and tibia. After 12 months, the researchers found no statistically or clinically significant difference between the two groups.

1 | INTRODUCTION

Childhood cancer survivors (CCS) have an increased risk for late complications including decreased bone mineral density (BMD) and related fractures.^{1,2} Up to 65% of CCS show low BMD dependent on treatment and cancer history. This is partly explained by an impairment in peak bone mass acquisition due to direct or indirect (eg, growth hormone deficiency and hypogonadism) effects of chemotherapy and radiotherapy as well as the cancer itself.¹⁻³ Furthermore, childhood cancer patients during and after cancer treatment frequently experience side effects such as fatigue, nausea, pain and depression that negatively influence bone acquisition through lack of physical activity (PA) or nutritional deficits.^{1,2,4} Moreover, reduced PA levels often persist after cancer therapy.^{2,4-6} Although evidence is scarce, international follow-up guidelines for childhood cancer survivors recommend regular weightbearing exercises such as running and jumping as part of aftercare even during adulthood to maintain or improve bone health.⁷

A physically active lifestyle has in general been associated with improved overall health, lowered risk of developing cancer and increased bone health.^{8,9} Evidence shows that adult cancer patients benefit from regular exercise for multiple cancer-related adverse effects; including physical functioning, fatigue, sexual function, psychological well-being and quality of life.^{10,11} Yet, the body of knowledge on benefits of exercise on bone health among CCS remains sparse and controversial.^{2,12} Some small or exploratory observational studies found a

positive association between PA and BMD among young CCS.¹³⁻¹⁷ A one-year randomized controlled trial (RCT) observed that low-magnitude mechanical stimulation improved whole-body BMD among young CCS while tibial trabecular BMD improved among those with highest intervention-adherence.¹⁸ Another study, however, found no effect on BMD following a 2-year exercise program among children with leukemia.¹⁹ There is thus a striking lack of intervention studies that investigate exercise benefits on bone health in CCS.

In our study, we performed a RCT that included a 1 year individualized, partially supervised general exercise program in a sample of adolescent and adult CCS.²⁰ We looked at the effects of regular general exercise training on lower body densitometric and architectural bone outcomes measured by dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT), defined as secondary endpoints of the SURfit trial. We hypothesized that our exercise program would benefit lower body bone health.

2 | METHODS

2.1 | Study design and participants

Data for this publication were drawn from the SURfit study (ClinicalTrials.gov identifier: NCT02730767).²⁰ SURfit was a single-center, two-armed (parallel) superiority RCT with a one-year PA



FIGURE 1 CONSORT diagram

intervention for adolescent and adult CCS. It was conducted at the University Children's Hospital Basel, Switzerland, between September 2015 and February 2019. The objectives of SURfit were to assess the effects of a 1 year exercise program on cardiovascular health (primary outcome), and among others on bone health (secondary outcome) in CCS. We included CCS diagnosed with cancer based on the International Classification of Childhood Cancer, third edition,²¹ or Langerhans cell histiocytosis treated at a Swiss Pediatric Oncology Group clinic, aged \geq 16 years at enrollment, <16 years at diagnosis and \geq 5 years since the last cancer event.

2.2 | Procedures

Eligible CCS were identified from the national, population-based Childhood Cancer Registry²² and contacted by letter between June 2015 and February 2018 (see Figure 1). Eligible CCS who consented to participate were randomly allocated 1:1 with (web-based) minimization randomization by a person independent of the study. Stratification factors for the minimization were gender and four cancer categories (leukemia/lymphoma, central nervous system tumors, bone tumors/soft tissue sarcomas or other tumor diagnoses). Assessments were performed at baseline (T0) and after 12 months (T12). Blinding of assessors was assured for DXA and the statistical analyses.

2.3 | Bone outcomes

Bone health was measured by pQCT (XCT 2000; Stratec Medical, Pforzheim, Germany) and DXA (Discovery A densitometer; Hologic, Bedford, MA). Quality assurance of both devices was checked and if needed calibrated before each measuring day according to manufacturers' guidelines. Volumetric BMD, bone mass and bone geometry were measured using pQCT at the distal epiphysis (4%) and diaphysis (66%) of the tibia in the nondominant lower leg.²⁰ Bone outcome parameters were defined a priori by experts and were total and trabecular volumetric BMD at 4% of tibia length, cortical volumetric BMD, total cortical cross-sectional area and strength-strain index at

@uicc

66% tibia length. Outcomes by DXA included femoral neck, total hip and lumbar spine areal BMD by age and gender matched z-scores.²³ Supplemental Appendix 1 provides the rationale for some changes in the bone outcome parameters from the ones preregistered in the clinical trials registry.

2.4 | Covariates

Demographic and medical information was extracted from medical records or measured at baseline.²⁰ Lean body and fat mass were measured by DXA and muscular cross-sectional area at tibia 66% by pQCT. PA at baseline was assessed by ActiGraph GT3X+ (Pensacola, FL) accelerometer (100 Hz, 60 seconds epochs). Daily minutes spent in moderate-to-vigorous PA averaged across all valid days (>10 hours wear-time between 6 AM and 10 PM) were calculated using ActiLife v6.13.4.²⁴ Cardiopulmonary exercise testing (CPET) on a stationary bike was used to estimate change in maximum peak performance in Watts between baseline and postintervention.²⁰ Smoking status, vitamin D supplementation and calcium supplementation were assessed through self-reported standardized questionnaires.

2.5 | Intervention and control conditions

The intervention group was asked to add ≥2.5 hours of intense PA/week. Intense PA programs were developed with a professional coach (physiotherapist) and comprised 2 hours aerobic and 0.5 hours of strength building exercises. Regular contact with the coach (faceto-face at 0. 3. 6 and 12 months, and phone calls after 1. 2. 4. 5. 8 and 10 months), pedometers, and a self-administered web-based daily activity diary for the 1 year study duration were used as motivational tools. Participants were reminded weekly of missing diary entries. The control group was asked to keep their activity levels constant.²⁰ Compliance to the intervention/control group was defined as: (a) reported compliance includes only participants of the intervention group who reached $\geq 2/3$ of the intense PA goal (web-based diary, missing values were either set to 0 minute daily PA or imputed with participant's yearly PA mean) and controls who reported ≤30 minutes increase in intense weekly PA (questionnaire); and (b) assumed compliance allocates participants to the intervention group if they improved peak work rate by ≥5% from T0 to T12 by CPET irrespective of their randomized treatment allocation. Participants with less increase in work rate were handled as controls. Only the following exercise tests were taken into consideration: either maximal or submaximal (submaximal at same level) effort at both time points, or improvement of performance despite less effort at T12.

2.6 | Statistical analyses

Required sample size for SURfit was estimated based on the primary trial endpoint (cardiovascular disease risk score) and resulted in

60 participants in each arm.²⁰ We aimed at 150 participants to account for a 20% dropout rate. All statistical analyses were predefined (before unblinding of the data) and detailed in the statistical analysis plan. Group differences in bone parameters were estimated using analyses of covariance (ANCOVA) adjusted for age, minimization randomization factors (sex and tumor type), and baseline bone outcomes. Beta coefficients (Beta) with 95% confidence intervals (95% CI) are shown for all models. Relative changes of Beta were calculated based on baseline parameters. A P-value ≤.05 was considered statistically significant. For graphical illustration, z-standardized beta coefficients were used.²³ The following prespecified analyses were performed according to the study protocol²⁰: Intention-to-treat (ITT) with last observation carried forward (LOCF) as primary analysis was conducted. Further prespecified analyses included complete case analysis, per protocol analyses (PP) based on reported (online diary entries) and assumed (Watt performance on stationary bike) compliance, and a dose response assessment as described in Supplemental Appendix 2. Exploratory subgroup analyses were performed for bone parameters of intervention participants showing low BMD (zscore ≤ -1) at baseline²⁵ by adding an interaction term between group allocation and low baseline BMD in those without missing outcome measures. R v4.0.2²⁶ was used for regression data analyses and graphical plotting.

3 | RESULTS

3.1 | Study sample

From 1450 eligible CCS, 842 were invited and received basic study information. A total of 151 CCS (18%) were eligible and randomly assigned to one of the two treatment arms of which 132 (87%) completed the entire study; 13 participants from the intervention group and 6 controls (together 13%) dropped out for various reasons (Figure 1).

Mean age at baseline of the 151 participants was 30.4 ± 8.6 years (range 17-49 years); 66 (44%) were female (Table 1). Tumor type, treatment, bone parameters and PA were well matched between groups.

3.2 | Analysis sets and intervention adherence

All 75 control and 76 intervention group participants were considered in the ITT and complete case analysis. Based on reported compliance, 63% (n = 47) of controls and 46% (n = 35) of intervention participants completed their treatment as allocated when missing diary entries were set to 0 minute PA/day, and 53% (n = 40) of interventions when participant's yearly PA mean was used, respectively. Based on assumed compliance (improvement in Watt performance), 76 (50%) behaved as controls (42 from control, 34 from intervention group), 36 (24%, 18 from each group) as participants of the intervention group and 39 (26%) could not be allocated due to missing information Culcc

Intervention (n = 76) Control (n = 75) Basic characteristics 33 (43%) 33 (44%) Sex, female 33 (43%) 33 (44%) Age at study (y) 31.5 (8.3) 29.3 (8.7) Height (cm) 170.1 (8.9) 171.3 (9.7) Weight (kg) 71.0 (15.3) 70.0 (15.5) Body composition 34.4 (4.3) 23.7 (4.0) DXA lean body mass (kg) 24.4 (4.3) 23.7 (4.0) DXA tact most (kg) 22.6 (6.6) 21.9 (6.8) pQCT tibia 66% muscular CSA (mm ²) 6176 (1104) 6076 (1212) Cancer related information 7.4 (5.1) 7.3 (4.6) Time since diagnosis (y) 7.6 (5.1) 7.3 (4.6) Time since diagnosis (y) 7.6 (5.1) 7.3 (4.6) CLCC-3 cancer diagnoses 11 14.1%) II-Leukemia 24 (32%) 31 (41%) II-Leukemia 2 (33.) 3 (4%) VIII-Malignant bone tumors 13 (17%) 38 (24%) VIII-Malignant bone tumors 2 (31.117%) 31 (45%) Chemotherapy 4 (55%) <t< th=""><th></th><th></th><th></th></t<>			
Sex, female33 (43%)33 (44%)Age at study (y)31.5 (8.3)29.3 (8.7)Height (cm)170.1 (8.9)171.3 (9.7)Weight (kg)71.0 (15.3)70.0 (15.5)Body compositionBody compositionBM (kg/m²)24.4 (4.3)23.7 (4.0)DXA lean body mass (kg)46.7 (10.1)46.1 (9.6)DXA fat mass (kg)22.6 (6.6)21.9 (6.8)pQCT tibia 66% muscular CSA (mm²)26.0 (10.1)7.3 (4.6)DXA fat mass (kg)7.6 (5.1)7.3 (4.6)pQCT tibia 66% muscular CSA (mm²)24.0 (8.5)22.0 (9.2)ICCC-3 cancer diagnosis (y)7.6 (5.1)7.3 (4.6)Time since diagnosis (y)24.0 (8.5)22.0 (9.2)ICCC-3 cancer diagnoses11.1 (14%)6 (8%)III-Leukemia24.3 (23%)31.4 (13%)III-Leukemia2.3 (3%)3 (4%)III-Leukemia2.1 (3%)3 (4%)III-Leukemia2.1 (3%)3 (4%)III-Leukemia2.1 (3%)3 (4%)III-Leukemia2.1 (3%)3 (4%)III-Leukemia2.1 (3%)3 (4%)III-Leukemia3 (4%)3 (4%)III-Leukemia2.1 (3%)3 (4%)III-Leukemia2.1 (3%)3 (4%)III-Leukemia3 (3%)3 (4%)III-Leukemia3 (3%)3 (4%)III-Leukemia3 (3%)3 (4%)III-Leukemia3 (3%)3 (4%)III-Leukemia3 (3%)3 (4%)III-Leukemia3 (1%)3			
Age at study (v) 31.5 (k.) 29.3 (k.7) Height (cm) 170.1 (8.9) 171.3 (9.7) Weight (kg) 71.0 (15.3) 70.0 (15.5) Body composition BMI (kg/m?) 24.4 (4.3) 23.7 (4.0) DXA lean body mass (kg) 46.7 (10.1) 46.1 (9.6) DXA fat mass (kg) 22.6 (6.6) 21.9 (6.8) pQCT tibia 66% muscular CSA (mm²) 6176 (1104) 6076 (1212) Cancer related information Age at diagnosis (y) 7.6 (5.1) 7.3 (4.6) Time since diagnosis (y) 24.0 (8.5) 22.0 (9.2) ICCC-3 cancer diagnoses 14 (19%) III-Leukemia 24 (32%) 31 (41%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) VIII-Malignant bone tumors 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (6	Basic characteristics		
Height (cm) 170.1 (8.9) 171.3 (9.7) Weight (kg) 71.0 (15.3) 70.0 (15.5) Body composition T1.0 (15.3) 70.0 (15.5) BMI (kg/m ²) 24.4 (4.3) 23.7 (4.0) DXA lean body mass (kg) 46.7 (10.1) 46.1 (9.6) DXA fat mass (kg) 22.6 (6.6) 21.9 (6.8) pQCT tibia 66% muscular CSA (mm ²) 6176 (1104) 6076 (1212) Cancer related information Time since diagnosis (y) 7.6 (5.1) 7.3 (4.6) Time since diagnosis (y) 24.0 (8.5) 22.0 (9.2) 12CC-3 cancer diagnoses I-Leukemia 24 (32%) 31 (41%) 14 (19%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) IX-Soft tissue and other extraosseous 8 (11%) 3 (4%) Other tumors 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (m/m ²)* 192 (89) 194 (98) Received anthracycline therapy 42 (15%) 45 (20%) Cumula	Sex, female	33 (43%)	33 (44%)
Weight (kg) 71.0 (15.3) 70.0 (15.5) Body composition BMI (kg/m ²) 24.4 (4.3) 23.7 (4.0) DXA lean body mass (kg) 46.7 (10.1) 46.1 (9.6) DXA fat mass (kg) 22.6 (6.6) 21.9 (6.8) pQCT tibia 66% muscular CSA (mm ²) 6176 (1104) 6076 (1212) Cancer related information 44.0 (8.5) 22.0 (9.2) ICCC-3 cancer diagnoses 11 (14%) 6 (8%) III-Leukemia 24 (32%) 31 (41%) II-Leukemia 24 (32%) 31 (41%) III-Lymphoma 18 (24%) 14 (19%) III-Leukemia 24 (32%) 34(%) VIII-Malignant bone tumors 2 (3%) 3 (4%) VIII-Malignant bone tumors 13 (17%) 18 (24%) Other tumors 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (mg/m ²) ⁶ 192 (89) 194 (98) Received anthracycline therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) ⁶ 10 (13%)	Age at study (y)	31.5 (8.3)	29.3 (8.7)
Body composition Second s	Height (cm)	170.1 (8.9)	171.3 (9.7)
BMI (kg/m ²) 24.4 (4.3) 23.7 (4.0) DXA lean body mass (kg) 46.7 (10.1) 46.1 (9.6) DXA fat mass (kg) 22.6 (6.6) 21.9 (6.8) pQCT tibia 66% muscular CSA (mm ²) 6176 (1104) 6076 (1212) Cancer related information Age at diagnosis (y) 7.6 (5.1) 7.3 (4.6) Time since diagnosis (y) 24.0 (8.5) 22.0 (9.2) ICCC-3 cancer diagnoses 1 14 (19%) I-Leukemia 24 (32%) 31 (41%) II-Lymphoma 18 (24%) 14 (19%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) DCher tumors 13 (17%) 18 (24%) Chemotherapy 2 (55%) 51 (68%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (mg/m ²) ⁶ 192 (89) 194 (98) Received athracycline therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) ⁶ 10 (13%) 10 (13%) Cumulative dose (mg/m ²) ⁶ 10 (13%)	Weight (kg)	71.0 (15.3)	70.0 (15.5)
DXA lean body mass (kg) 46.7 (10.1) 46.1 (9.6) DXA fat mass (kg) 22.6 (6.6) 21.9 (6.8) pQCT tibia 66% muscular CSA (mm²) 6176 (1104) 6076 (1212) 7.6 (5.1) 7.3 (4.6) Age at diagnosis (y) 7.6 (5.1) 7.3 (4.6) Time since diagnosis (y) 24.0 (8.5) 22.0 (9.2) ICCC-3 cancer diagnoses 1 14.19% I-Leukemia 24 (32%) 31 (41%) II-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) Other tumors 13 (17%) 18 (24%) Chemotherapy 3 (1%) 3 (4%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (mg/m²) ⁶ 4046 (3431) 4443 (3172) Received anthracycline therapy 42 (15%) 45 (60%) Cumulative dose (mg/m²) ⁶ 4046 (3431) 4443 (3172) Received cranial radiation therapy 12 (16%) 15 (20%) Cumulative dose (mg/m²) ⁶ 38 (20) 43 (20)	Body composition		
DXA fat mass (kg) 22.6 (6.6) 21.9 (6.8) pQCT tibia 66% muscular CSA (mm²) 6476 (1104) 6076 (1212) Cancer related information 7.3 (4.6) 7.3 (4.6) Time since diagnosis (y) 24.0 (8.5) 22.0 (9.2) ICCC-3 cancer diagnoses 1 1.4 (19%) I-Leukemia 24 (32%) 31 (41%) II-Lymphoma 18 (24%) 14 (19%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) Other tumors 13 (17%) 18 (24%) Other tumors 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (mg/m²)* 192 (89) 194 (98) Received anthracycline therapy 42 (55%) 45 (60%) Cumulative dose (mg/m²)* 4046 (3431) 4443 (3172) Received cranial radiation therapy 12 (16%) 15 (20%) Cumulative dose (mg/m²)* 38 (20) 43 (20) Stem cell transplantation 5 (7%) 3 (4%) Stomoker, yes <td>BMI (kg/m²)</td> <td>24.4 (4.3)</td> <td>23.7 (4.0)</td>	BMI (kg/m²)	24.4 (4.3)	23.7 (4.0)
pQCT tibla 66% muscular CSA (mm ²) 6176 (1104) 6076 (1212) Cancer related information	DXA lean body mass (kg)	46.7 (10.1)	46.1 (9.6)
Cancer related informationAge at diagnosis (y)7.6 (5.1)7.3 (4.6)Time since diagnosis (y)24.0 (8.5)22.0 (9.2)ICCC-3 cancer diagnosesII-Leukemia24 (32%)31 (41%)II-Lymphoma18 (24%)14 (19%)III-Central nervous system tumors11 (14%)6 (8%)VIII-Malignant bone tumors2 (3%)3 (4%)Other tumors13 (17%)18 (24%)Other tumors13 (17%)18 (24%)Chemotherapy45 (59%)51 (68%)Chemotherapy42 (55%)45 (60%)Cumulative dose (mg/m ²) ^a 192 (89)194 (98)Received anthracycline therapy42 (55%)45 (60%)Cumulative dose (mg/m ²) ^a 4046 (3431)4443 (3172)Radiation therapy12 (16%)15 (20%)Cranial radiation therapy12 (16%)10 (13%)Stem cell transplantation5 (7%)4 (5%)MVPA (min/day) ^b 38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)8 (11%) 5 (7%)5 (7%) 3 (4%)Duration of trial5 (7%)3 (4%)	DXA fat mass (kg)	22.6 (6.6)	21.9 (6.8)
Age at diagnosis (y)7.6 (5.1)7.3 (4.6)Time since diagnosis (y)24.0 (8.5)22.0 (9.2)ICCC-3 cancer diagnoses1I-Leukemia24 (32%)31 (41%)II-Lymphoma18 (24%)14 (19%)III-Central nervous system tumors11 (14%)6 (8%)VIII-Malignant bone tumors2 (3%)3 (4%)IX-Soft tissue and other extraosseous8 (11%)3 (4%)Other tumors13 (17%)18 (24%)Other tumors13 (17%)18 (24%)Chemotherapy45 (59%)51 (68%)Cumulative dose (mg/m ²) ^a 192 (89)194 (98)Received anthracycline therapy42 (55%)45 (60%)Cumulative dose (mg/m ²) ^a 4046 (3431)4443 (3172)Radiation therapy12 (16%)15 (20%)Cumulative dose (mg/m ²) ^a 38 (20)43 (20)Received cranial radiation therapy12 (16%)10 (13%)Stem cell transplantation5 (7%)3 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)8 (11%) 5 (7%)5 (7%) 3 (4%)Calcium supplement, yes (within last 3 months)5 (7%) 3 (34%)3 (4%)Duration of trial5 (7%)3 (4%)	pQCT tibia 66% muscular CSA (mm ²)	6176 (1104)	6076 (1212)
Time since diagnosis (y) 24.0 (8.5) 22.0 (9.2) ICCC-3 cancer diagnoses 31 (41%) I-Leukemia 24 (32%) 31 (41%) II-Lymphoma 18 (24%) 14 (19%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) IX-Soft tissue and other extraosseous 8 (11%) 3 (4%) Other tumors 13 (17%) 18 (24%) Chemotherapy 13 (17%) 18 (24%) Chemotherapy 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (mg/m ²) [®] 192 (89) 194 (98) Received athracycline therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) [®] 192 (89) 194 (98) Received steroid therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) [®] 192 (89) 194 (98) Received cranial radiation therapy 12 (16%) 15 (20%) Cranial radiation dose ≥24 Gy 10 (13%) 10 (13%) Stem cell transplantation 5 (7%) 3 (42) Smoker, yes 19 (25	Cancer related information		
ICCC-3 cancer diagnoses 24 (32%) 31 (41%) I-Leukemia 24 (32%) 31 (41%) II-Lymphoma 18 (24%) 14 (19%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) IX-Soft tissue and other extraosseous 8 (11%) 3 (4%) Other tumors 13 (17%) 18 (24%) Other tumors 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (mg/m ²) ^a 192 (89) 194 (98) Received athracycline therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) ^a 192 (89) 194 (98) Received steroid therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) ^a 4046 (3431) 4443 (3172) Radiation therapy 12 (16%) 15 (20%) Cranial radiation therapy 12 (16%) 10 (13%) Tealth behavior 5 (7%) 3 (45%) MVPA (min/dayl ^b) 38 (20) 43 (20) Smoker, yes 19 (25%) 16 (21%) Yitamin D supplement, yes (within last 3 m	Age at diagnosis (y)	7.6 (5.1)	7.3 (4.6)
I-Leukemia 24 (32%) 31 (41%) II-Lymphoma 18 (24%) 14 (19%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) IX-Soft tissue and other extraosseous 8 (11%) 3 (4%) Other tumors 13 (17%) 18 (24%) Other tumors 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (68%) Chumulative dose (mg/m ²) ^a 192 (89) 194 (98) Received anthracycline therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) ^a 4046 (3431) 4443 (3172) Radiation therapy 12 (16%) 15 (20%) Cumulative dose (mg/m ²) ^a 4046 (3431) 10 (13%) Received cranial radiation therapy 12 (16%) 15 (20%) Cranial radiation dose ≥24 Gy 10 (13%) 10 (13%) Stem cell transplantation 5 (7%) 3 (20) Smoker, yes 19 (25%) 16 (21%) Vitamin D supplement, yes (within last 3 months) 5 (7%) 3 (4%) Calcium supplement, yes (within last 3 months) 5 (7%) 3 (4%)	Time since diagnosis (y)	24.0 (8.5)	22.0 (9.2)
II-Lymphoma 18 (24%) 14 (19%) III-Central nervous system tumors 11 (14%) 6 (8%) VIII-Malignant bone tumors 2 (3%) 3 (4%) IX-Soft tissue and other extraosseous 8 (11%) 3 (4%) Other tumors 13 (17%) 18 (24%) Other tumors 13 (17%) 18 (24%) Chemotherapy 13 (17%) 18 (24%) Chemotherapy 45 (59%) 51 (68%) Cumulative dose (mg/m ²) ^a 192 (89) 194 (98) Received steroid therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) ^a 4046 (3431) 4443 (3172) Radiation therapy 12 (16%) 15 (20%) Cranial radiation therapy 12 (16%) 10 (13%) Stem cell transplantation 5 (7%) 4 (5%) MVPA (min/dayl ^b 38 (20) 43 (20) Smoker, yes 19 (25%) 16 (21%) Vitamin D supplement, yes (within last 8 (11%) 5 (7%) 3 months) 5 (7%) 3 (4%) 3 months) 5 (7%) 3 (4%) <td>ICCC-3 cancer diagnoses</td> <td></td> <td></td>	ICCC-3 cancer diagnoses		
III-Central nervous system tumors11 (14%)6 (8%)VIII-Malignant bone tumors2 (3%)3 (4%)VIII-Malignant bone tumors2 (3%)3 (4%)IX-Soft tissue and other extraosseous8 (11%)3 (4%)Other tumors13 (17%)18 (24%)Other tumors13 (17%)18 (24%)Chemotherapy45 (59%)51 (68%)Cumulative dose (mg/m ²) ^a 192 (89)194 (98)Received steroid therapy42 (55%)45 (60%)Cumulative dose (mg/m ²) ^a 4046 (3431)4443 (3172)Radiation therapy12 (16%)15 (20%)Cranial radiation therapy12 (16%)10 (13%)Stem cell transplantation5 (7%)4 (5%)Health behavior19 (25%)16 (21%)MVPA (min/day) ^b 38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)5 (7%) 3 (4%) 3 months)3 (4%)Calcium supplement, yes (within last 3 months)5 (7%) 3 (4%)3 (4%)	I—Leukemia	24 (32%)	31 (41%)
VIII-Malignant bone tumors2 (3%)3 (4%)IX-Soft tissue and other extraosseous8 (11%)3 (4%)Other tumors13 (17%)18 (24%)Other tumors13 (17%)18 (24%)Chemotherapy45 (59%)51 (68%)Cumulative dose (mg/m²)a192 (89)194 (98)Received steroid therapy42 (55%)45 (60%)Cumulative dose (mg/m²)a4046 (3431)4443 (3172)Radiation therapy22 (16%)15 (20%)Cranial radiation therapy12 (16%)15 (20%)Cranial radiation dose ≥24 Gy10 (13%)10 (13%)Stem cell transplantation5 (7%)4 (5%)Health behavior19 (25%)16 (21%)MVPA (min/day)b38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)5 (7%)3 (4%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	II—Lymphoma	18 (24%)	14 (19%)
IX-Soft tissue and other extraosseous8 (11%)3 (4%)Other tumors13 (17%)18 (24%)Chemotherapy13 (17%)18 (24%)Received anthracycline therapy45 (59%)51 (68%)Cumulative dose (mg/m ²) ^a 192 (89)194 (98)Received steroid therapy42 (55%)45 (60%)Cumulative dose (mg/m ²) ^a 4046 (3431)4443 (3172)Radiation therapy42 (16%)4443 (3172)Radiation therapy12 (16%)15 (20%)Cranial radiation therapy12 (16%)15 (20%)Stem cell transplantation5 (7%)4 (5%)Health behavior19 (25%)16 (21%)MVPA (min/day) ^b 38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)5 (7%)3 (4%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	III–Central nervous system tumors	11 (14%)	6 (8%)
Other tumors13 (17%)18 (24%)Chemotherapy118 (24%)Received anthracycline therapy45 (59%)51 (68%)Cumulative dose (mg/m²)a192 (89)194 (98)Received steroid therapy42 (55%)45 (60%)Cumulative dose (mg/m²)a4046 (3431)4443 (3172)Radiation therapy4046 (3431)4443 (3172)Radiation therapy12 (16%)15 (20%)Cranial radiation therapy12 (16%)10 (13%)Stem cell transplantation5 (7%)4 (5%)Health behavior19 (25%)16 (21%)MVPA (min/day)b38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 (11%)5 (7%)3 months)5 (7%)3 (4%)Calcium supplement, yes (within last 3 months)5 (7%)Duration of trial5 (7%)3 (4%)	VIII—Malignant bone tumors	2 (3%)	3 (4%)
Chemotherapy45 (59%)51 (68%)Received anthracycline therapy45 (59%)51 (68%)Cumulative dose (mg/m ²) ^a 192 (89)194 (98)Received steroid therapy42 (55%)45 (60%)Cumulative dose (mg/m ²) ^a 4046 (3431)4443 (3172)Radiation therapy42 (16%)4443 (3172)Radiation therapy12 (16%)15 (20%)Cranial radiation therapy12 (16%)15 (20%)Cranial radiation dose ≥24 Gy10 (13%)10 (13%)Stem cell transplantation5 (7%)4 (5%)Health behaviorMVPA (min/day) ^b 38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 (11%)5 (7%)3 (4%)3 months)5 (7%)3 (4%)Calcium supplement, yes (within last 3 nonths)Duration of trial	IX—Soft tissue and other extraosseous	8 (11%)	3 (4%)
Received anthracycline therapy45 (59%)51 (68%)Cumulative dose (mg/m²)³192 (89)194 (98)Received steroid therapy42 (55%)45 (60%)Cumulative dose (mg/m²)³4046 (3431)4443 (3172)Radiation therapy4046 (3431)4443 (3172)Radiation therapy12 (16%)15 (20%)Cranial radiation therapy12 (16%)10 (13%)Stem cell transplantation5 (7%)4 (5%)Health behavior19 (25%)16 (21%)MVPA (min/day) ⁶ 38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 (11%)5 (7%)3 months)5 (7%)3 (4%)Calcium supplement, yes (within last 3 months)5 (7%)Duration of trial5 (7%)3 (4%)	Other tumors	13 (17%)	18 (24%)
Cumulative dose (mg/m²)a192 (89)194 (98)Received steroid therapy42 (55%)45 (60%)Cumulative dose (mg/m²)a4046 (3431)4443 (3172)Radiation therapy4046 (3431)4443 (3172)Radiation therapy12 (16%)15 (20%)Cranial radiation therapy12 (16%)15 (20%)Cranial radiation dose ≥24 Gy10 (13%)10 (13%)Stem cell transplantation5 (7%)4 (5%)Health behaviorMVPA (min/day)b38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)5 (7%)3 (4%) 3 (4%) 3 (4%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	Chemotherapy		
Received steroid therapy 42 (55%) 45 (60%) Cumulative dose (mg/m ²) ^a 4046 (3431) 4443 (3172) Radiation therapy 42 (16%) 4443 (3172) Radiation therapy 12 (16%) 15 (20%) Cranial radiation therapy 12 (16%) 10 (13%) Cranial radiation dose ≥24 Gy 10 (13%) 10 (13%) Stem cell transplantation 5 (7%) 4 (5%) Health behavior 5 (7%) 38 (20) 43 (20) MVPA (min/day) ^b 38 (20) 43 (20) 16 (21%) Smoker, yes 19 (25%) 16 (21%) 5 (7%) Smoker, yes (within last 3 months) 5 (7%) 3 (4%) 5 (7%) Calcium supplement, yes (within last 3 months) 5 (7%) 3 (4%) 3 (4%) Sumoths 5 (7%) 3 (4%) 3 (4%) Autor of trial 5 (7%) 3 (4%) 3 (4%)	Received anthracycline therapy	45 (59%)	51 (68%)
Cumulative dose (mg/m ²) ^a 4046 (3431) 4443 (3172) Radiation therapy 12 (16%) 15 (20%) Received cranial radiation therapy 12 (16%) 10 (13%) Cranial radiation dose ≥24 Gy 10 (13%) 10 (13%) Stem cell transplantation 5 (7%) 4 (5%) Health behavior 7 4 (5%) MVPA (min/day) ^b 38 (20) 43 (20) Smoker, yes 19 (25%) 16 (21%) Vitamin D supplement, yes (within last 3 (11%) 5 (7%) 3 (4%) 3 months) 5 (7%) 3 (4%) Calcium supplement, yes (within last 3 months) 5 (7%) 3 (4%)	Cumulative dose (mg/m ²) ^a	192 (89)	194 (98)
Radiation therapy12 (16%)15 (20%)Received cranial radiation therapy12 (16%)10 (13%)Cranial radiation dose \geq 24 Gy10 (13%)10 (13%)Stem cell transplantation5 (7%)4 (5%)Health behaviorMVPA (min/day) ^b 38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)8 (11%)5 (7%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial	Received steroid therapy	42 (55%)	45 (60%)
Received cranial radiation therapy 12 (16%) 15 (20%) Cranial radiation dose ≥24 Gy 10 (13%) 10 (13%) Stem cell transplantation 5 (7%) 4 (5%) Health behavior 7 7 MVPA (min/day) ^b 38 (20) 43 (20) Smoker, yes 19 (25%) 16 (21%) Vitamin D supplement, yes (within last 3 (11%) 5 (7%) 3 (4%) 3 months) 5 (7%) 3 (4%) Calcium supplement, yes (within last 3 months) 5 (7%) 3 (4%)	Cumulative dose (mg/m ²) ^a	4046 (3431)	4443 (3172)
Cranial radiation dose ≥24 Gy 10 (13%) 10 (13%) Stem cell transplantation 5 (7%) 4 (5%) Health behavior 10 (13%) 4 (5%) MVPA (min/day) ^b 38 (20) 43 (20) Smoker, yes 19 (25%) 16 (21%) Vitamin D supplement, yes (within last 3 months) 8 (11%) 5 (7%) Calcium supplement, yes (within last 3 months) 5 (7%) 3 (4%) Duration of trial 10 (13%) 10 (13%)	Radiation therapy		
Stem cell transplantation5 (7%)4 (5%)Health behavior38 (20)43 (20)MVPA (min/day) ^b 38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)8 (11%)5 (7%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	Received cranial radiation therapy	12 (16%)	15 (20%)
Health behaviorMVPA (min/day)b38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)8 (11%)5 (7%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	Cranial radiation dose ≥24 Gy	10 (13%)	10 (13%)
MVPA (min/day)b38 (20)43 (20)Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)8 (11%)5 (7%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	Stem cell transplantation	5 (7%)	4 (5%)
Smoker, yes19 (25%)16 (21%)Vitamin D supplement, yes (within last 3 months)8 (11%)5 (7%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	Health behavior		
Vitamin D supplement, yes (within last 3 months)8 (11%)5 (7%)Calcium supplement, yes (within last 3 months)5 (7%)3 (4%)Duration of trial5 (7%)3 (4%)	MVPA (min/day) ^b	38 (20)	43 (20)
3 months) Calcium supplement, yes (within last 5 (7%) 3 (4%) 3 months) Duration of trial	Smoker, yes	19 (25%)	16 (21%)
3 months) Duration of trial		8 (11%)	5 (7%)
		5 (7%)	3 (4%)
Duration (wk) 56.4 (3.5) 56.3 (3.5)	Duration of trial		
	Duration (wk)	56.4 (3.5)	56.3 (3.5)

JUNG ET AL.

TABLE 1Baseline characteristics ofthe SURfit study participants (n = 151)

Note: Data are presented as n (%)/mean (SD). Number of participants included (intervention/control): DXA: n = 74/73; pQCT: n = 71/71; physical activity: n = 62/67; smoker: n = 76/73; vitamin D supplement: n = 74/72; calcium supplement: n = 74/71.

Abbreviations: CSA, cross-sectional area; DXA, dual-energy x-ray absorptiometry; ICCC-3, International Classification for Childhood Cancer—third edition; MVPA, moderate to vigorous physical activity; pQCT, peripheral quantitative computed tomography.

^aIn those who received therapy.

 $^{\mathrm{b}}\mathsf{D}\mathsf{e}\mathsf{termined}$ by ActiGraph GT3X+ accelerometer.

TABLE 2 Intervention effects on bone parameters from primary analysis (intention-to-treat with last observation carried forward)

	Intervention	ntervention			Adjusted difference at 12 mor	nths
	Baseline	12 months	Baseline	12 months	Beta (95% CI)	P value
DXA						
Femoral Neck BMD (g/cm ²)	0.83 (0.11)	0.84 (0.10)	0.85 (0.13)	0.85 (0.13)	0.007 (-0.002 to 0.017)	.12
Hip BMD (g/cm ²)	0.95 (0.10)	0.96 (0.10)	0.96 (0.12)	0.96 (0.12)	0.002 (-0.006 to 0.010)	.65
Lumbar Spine BMD (g/cm ²)	1.00 (0.11)	1.00 (0.11)	1.00 (0.11)	1.01 (0.11)	-0.003 (-0.011 to 0.005)	.44
pQCT						
T4 Total BMD (mg/cm ³)	304.1 (35.1)	305.5 (35.2)	305.1 (39.7)	305.1 (39.1)	1.209 (-0.717 to 3.136)	.22
T4 Trabecular BMD (mg/cm ³)	240.9 (31.6)	242.3 (31.4)	240.4 (35.5)	240.2 (34.6)	1.731 (-0.421 to 3.882)	.11
T66 Cortical BMD (mg/cm ³)	1136.0 (26.4)	1136.6 (26.3)	1139.5 (26.6)	1141.3 (26.0)	-0.539 (-2.649 to 1.572)	.62
T66 Cortical CSA (mm ²)	319.6 (51.6)	320.5 (51.4)	312.8 (45.8)	314.0 (46.2)	-0.004 (-1.107 to 1.098)	.99
T66 SSI (mm ³)	2223.9 (513.2)	2227.4 (515.9)	2152.0 (498.7)	2160.5 (485.7)	-0.794 (-19.373 to 17.785)	.93

Note: Intention-to-treat analyses with last observation carried forward. Group differences were analyzed using analysis of covariance (ANCOVA) adjusted for age, sex, tumor type and baseline bone. Data are presented as means (SD). Number of participants included in analyses (intervention/control): Femoral neck and hip BMD: n = 75/72; lumbar spine BMD: n = 74/72; tibia 4%: n = 76/74; tibia 66%: n = 73/72.

Abbreviations: BMD, bone mineral density; CSA, cross-sectional area; DXA, dual-energy x-ray absorptiometry; pQCT, peripheral quantitative computed tomography; SSI, strain strength index; T4, tibia 4% (distal epiphysis); T66, tibia 66% (diaphysis).



Adjusted marginal mean differences between the FIGURE 2 intervention and control group from baseline to 1-year follow-up for densitometric and architectural bone parameters (adjusted for sex, tumor type, bone parameters at baseline and age). Effects were estimated by ANCOVA models using an intention-to-treat approach (missing items were imputed by last observation carried forward). Effect estimates with 95% CI are expressed as unstandardized beta for DXA z-scores (age and gender matched norms²³) and as zstandardized beta coefficients for pQCT (in order to compare all estimates in the same figure). Positive effects indicate changes in favor of the intervention group. BMD, bone mineral density; CSA, cross-sectional area; DXA, dual-energy x-ray absorptiometry; pQCT, peripheral quantitative computed tomography; SSI, strength-strain index; T4, distal epiphysis (4%) of the tibia; T66, diaphysis (66%) of the tibia.

on Watt performance change (19 dropouts, 3 declined test, 17 with invalid max/submax categorization). Dose-response analysis was based on complete cases set. For the explorative subgroup analysis, 130 participants had complete data on trabecular BMD, while 62 (48%) were intervention participants (thereof 10 CCS with a z-score ≤ -1 at baseline).

INTERNATIONAL

JOURNAL of CANCER

JJC

3.3 | Effects of exercise on bone parameters

Neither ITT with LOCF (Table 2 and Figure 2, primary analysis) nor complete case analysis (Table S1) revealed statistically significant differences from T0 to T12 between intervention and control group for any bone measurements. Prespecified PP with reported compliance (online-diary based; Tables S2-S5) showed a significant larger increase in femoral neck BMD by 0.013 to 0.015 g/cm² (corresponds to 1.6%-1.8%) for LOCF and complete case analysis comparing the intervention to the control group. PP with assumed compliance (CPET peak Watt performance based; Table S6) revealed a significant larger increase in trabecular BMD by 3.597 mg/cm³ (1.5%) comparing the intervention to the control group. Dose response analysis (Table S7) did not show significant intervention effects. The exploratory subgroup analyses showed that trabecular BMD increased by 6.848 mg/cm³ (2.8%) more in intervention participants starting at low trabecular BMD (z-score ≤-1) compared to those with BMD z-score >-1 (Table 3).

4 | DISCUSSION

This novel RCT that investigated the effect of a tailored 1 year exercise program for adolescent and adult CCS (n = 151, 44% female) on lower body bone parameters as secondary outcome in the SURfit study found no effects in its primary ITT analysis. Nevertheless, predefined per protocol analyses found that CCS who *reported*

.1 C

	Beta (95% CI)	P-value
DXA		
Femoral neck BMD (g/cm ²)	0.006 (-0.019 to 0.030)	.83
Hip BMD (g/cm ²)	0.001 (-0.023 to 0.025)	.99
Lumbar spine BMD (g/cm ²)	-0.006 (-0.024 to 0.011)	.65
pQCT		
T4 total BMD (mg/cm ³)	-0.757 (-5.361 to 3.847)	.91
T4 trabecular BMD (mg/cm ³)	6.848 (0.470 to 13.226)	.03

Note: Exploratory subgroup analyses were performed for bone parameters of intervention participants showing low BMD (z-score ≤ -1) compared to those starting at BMD z-score ≥ -1 at baseline by adding an interaction term between group allocation and low baseline BMD to the analysis. Data are presented as mean (SD). Number of participants included in analyses (intervention-low BMD/control-low BMD): Femoral neck: n = 62-13/76-18: hip BMD: n = 62-7/76-12; lumbar spine BMD: n = 61-22/66-22; tibia 4%: n = 62-26/68-31; tibia 66%: n = 62-10/68-17.

Abbreviations: BMD, bone mineral density; DXA, dual-energy x-ray absorptiometry; pQCT, peripheral quantitative computed tomography; T4, Tibia 4% (distal epiphysis).

compliance to the intervention significantly improved femoral neck BMD by 1.6% to 1.8% more than controls. Likewise, those with *assumed compliance* improved distal tibia trabecular BMD by 1.5% more than their counterparts. Based on further exploratory analysis, intervention group participants starting at low trabecular BMD (*z*-score $(-1)^{25}$ improved their density by 2.8% more than those starting with BMD z-scores $(-1)^{25}$ or gram, not specifically designed to promote bone health, may therefore not be sufficient to promote bone density and structure of lower body bones.

This paper's null results may be due to the exercise program of SURfit that mainly included aerobic exercise aimed and powered to improve predominantly its primary endpoint of cardiovascular disease risk, and only secondarily affecting bone health.²⁰ Although a considerable number of CCS showed low BMD,²⁷ the majority of CCS in our study were in the normal range comparable to healthy adults.²⁸ Nevertheless, bone health of CCS can benefit from PA when being exposed already to a relatively low number of high mechanical impact peaks (roughly 300 impact repetitions/day for example, from jumping, running)²⁷ rather than through low impact training (eg, walking, cycling, swimming).^{27,29-33} Most CCS probably failed reaching this threshold within our individual PA program and thus, the program was not optimal to boosting bone remodeling. Our exercise program may have been more efficient if started earlier, as bone remodeling to physical loading is generally more prominent in younger, still growing CCS.^{30,32,34,35}

Our 1 year program was based on a carefully established concept that focused on different motivational tools to optimize intervention adherence.²⁰ Still, exercise adherence during and post cancer treatment is challenging and is more difficult to reach in long-term than short-term programs.^{12,36} Making personal PA goal attainment even more complicated, CCS often show a long history of low PA often introduced during cancer therapy.^{1,2,4,5,37} To change long-term habits for a period of 1 year might thus have been a motivational barrier for participating CCS. Indeed, only 46% of the intervention group **TABLE 3** Explorative subgroup analyses comparing intervention participants showing low (z-score ≤ -1) vs normal bone mineral density (zscore >-1)

reported a predefined two-thirds compliance of the expected training (\geq 100 minutes of addition intense PA/week). This may be an important reason why exercise trials are often unsuccessful at achieving clinically meaningful increases in bone health.¹⁹ These findings suggest a compliance problem in the intervention group and contamination within the control group, which is a well-known phenomenon in behavior-based RCTs that are based on self-selection.^{38,39}

We found an intervention effect on trabecular BMD of the femoral neck and distal tibia in those compliant compared to the noncompliant group. Even though all included CCS were willing to increase their weekly exercise workload, only 1 out of 2 documented enough exercise hours, and only 1 out of 4 of the intervention group increased their peak performance within 1 year. Moreover, 24% of controls increased their peak exercise performance which is a clear sign that these control group participants did indeed train against our agreement.

Improving bone health is especially important for those CCS who show low BMD already at a young age, a risk factor for osteoporosis and increased risk of fracture later in life.^{1,2} In accordance with a similar trial among child CCS,¹⁸ intervention group participants with low trabecular BMD at baseline improved more than those without osteopenia. Trabecular bone adapts its structure faster to changes in mechanical stimulation than cortical bone.⁴⁰ Cortical BMD temporarily decreases during the remodeling process before it can be mineralized.⁴¹ Hence, this improvement in trabecular bone might indicate the potential for a possible improvement in bone health with a more physically active lifestyle over a one-year period. This improvement in the architectural structure of bone is clinically relevant as it can be translated to a reduction in fragility fracture risk,^{32,42} especially once BMD reaches the osteoporotic fracture threshold.^{30,32} Comparable to our results, a BMD increase of 2% was sufficient in delaying this fracture threshold by several years.⁴² It is promising that especially those starting the training with osteopenia, or in other words who need it most, experienced the largest benefits from the study.

Strengths of our study include: it is one of the first exercise trial with a RCT design in a relatively large population of CCS, and the objective measures of bone densitometry and architecture by two methods (DXA and pQCT) were performed by trained staff at one single center. Assessors conducting DXA measurements and determining bone parameters were blinded. The program duration of 1 year was sufficient to allow for sustained changes in behavior, and in parallel to stimulate sufficient bone remodeling to detect clinically relevant effects on bone structure.^{43,44}

The major limitation is that the intervention was not mainly tailored to improve the secondary outcome of bone health, but rather cardiovascular health and therefore focused on a general exercise program. Only a minority of our adult CCS showed low bone mass for which clinical improvement is recommended.²⁸ Results from the per-protocol and exploratory analyses need to be interpreted carefully since they are prone to false positive findings and generally would need to be adjusted for pre- and postrandomization prognostic factors and multiple test-ing.⁴⁵ Sport adherence was based on self-declaration which is prone to desirability bias by overreporting.³⁸ Lastly, the larger dropout rate in the intervention group (17% vs 8% in controls), the cross-contamination of the control group, although common in such RCTs and the nature of the general exercise program might have contributed to the ITT based null effects. Reduced efficiency may have also arisen from the large heterogeneity of our study population for tumor history and levels of PA.

4.2 | Conclusion

To our knowledge, this is the first RCT with CCS investigating lower body bone health in an individualized 1 year exercise program. In the presence of only a small number of CCS with low BMD, there were no statistically and clinically significant differences between intervention and control group for changes in lower body bone parameters measured by DXA and pQCT in our primary analysis. Despite the overall null effects, we found weak evidence that our exercise program may have been beneficial for some clinically relevant bone parameters in the range between 1.5% and 2.8% in compliant participants and those with initial osteopenia. Nevertheless, our 1 year individual PA intervention may not have been specific and attractive enough to affect lower body bone health in young adult CCS two decades after cancer diagnosis. Thus, further studies should focus on younger, preferably still growing youth, predominantly on populations at risk with BMD z-score ≤ -1 , and on CCS during or shortly after treatment where the potential for bone adaptation is highest. Intervention programs should apply bone specific exercises that include high impact, bending and torsional forces known to strain bone with a layout that is attractive enough to maximize compliance.

AUTHOR CONTRIBUTIONS

Susi Kriemler, Nicolas X. von der Weid and Corina S. Rueegg designed the SURfit study; Helge Hebestreit supported the creation

of the study concept and the motivational tools of the intervention; Nicolas X. von der Weid, Christina Schindera, Simeon J. Zürcher, Ruedi Jung, Corina S. Rueegg, Susi Kriemler and Anna Schai conducted the SURfit study; Jonathan Schaeff designed and developed the web-based activity diary; Ruedi Jung and Simeon J. Zürcher analyzed pQCT data; Prisca Eser and Christian Meier supported pQCT and DXA analyses and interpretation; Cornelia Neuhaus supported physical activity implementation; Simeon J. Zürcher, Ruedi Jung conducted and Julia Braun, Corina S. Rueegg supported the statistical analyses; Simeon J. Zürcher, Ruedi Jung and Susi Kriemler interpreted results; Anna Schai contributed to subgroup analyses and their interpretation; Simeon J. Zürcher and Ruedi Jung, Susi Kriemler wrote the first draft of the manuscript: all authors commented on the manuscript and approved the final version. The work reported in the paper has been performed by the authors, unless clearly specified in the text.

ACKNOWLEDGEMENTS

We thank all participants for taking part in our study. We thank the study nurses, assistants, master students and physiotherapists for their great work within the study. Open access funding provided by Universitat Zurich.

FUNDING INFORMATION

Our study was supported by the Swiss Cancer League (KLS-3175-02-2013), the "Stiftung für krebskranke Kinder, Regio Basiliensis," "Gedächtnis-Stiftung Susy Rückert zur Krebsbekämpfung," "Taecker-Stiftung für Krebsforschung," "Stiftung Henriette & Hans-Rudolf Dubach-Bucher," "Stiftung zur Krebsbekämpfung," "Stiftung Krebs-Hilfe Zürich," "Fondation Recherche sur le Cancer de l'Enfant (FORCE)," Fond'Action contre le Cancer, and South-Eastern Norway Regional Health Authority (project number 2019039). Corina S. Rueegg has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under grant agreement n°609020-Scientia Fellows. Wie Hai Deng is paid by a research grant from the South-Eastern Norway Regional Health Authority (grant number 2019039, to Corina S. Rueegg). The funders had no role in the design of the study, the collection, analysis, interpretation of the data, writing of this manuscript or the decision to submit it for publication.

CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose.

DATA AVAILABILITY STATEMENT

The data will be shared on reasonable request to the corresponding author.

ETHICS STATEMENT

The study was approved by the Swiss Ethics Committee on research involving humans (Ethikkommission Nordwest- und Zentralschweiz). Written informed consent was obtained from each survivor prior to participation. Data were pseudonymized and safely stored compliant to data protection laws.

ORCID

Ruedi Jung https://orcid.org/0000-0001-9135-1495 Simeon J. Zürcher https://orcid.org/0000-0002-7759-747X Christina Schindera https://orcid.org/0000-0002-4511-287X Prisca Eser https://orcid.org/0000-0001-9734-0682 Christian Meier https://orcid.org/0000-0002-0619-821X Julia Braun https://orcid.org/0000-0001-8359-6177 Wei Hai Deng https://orcid.org/0000-0001-8194-9303 Helge Hebestreit https://orcid.org/0000-0002-9266-7149 Cornelia Neuhaus https://orcid.org/0000-0002-5698-6820 Corina S. Rueegg https://orcid.org/0000-0003-3720-4659 Nicolas X. von der Weid https://orcid.org/0000-0002-9555-3817 Susi Kriemler https://orcid.org/0000-0002-3384-7940

Culco

REFERENCES

- Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. *Pediatrics*. 2008;121:e705-e713.
- Wilson CL, Ness KK. Bone mineral density deficits and fractures in survivors of childhood cancer. *Curr Osteoporos Rep.* 2013;11:329-337.
- Chemaitilly W, Cohen LE. Diagnosis of endocrine disease: endocrine late-effects of childhood cancer and its treatments. *Eur J Endocrinol*. 2017;176:183-203.
- Spreafico F, Murelli M, Timmons BW, Massimino M, Barr R. Sport activities and exercise as part of routine cancer care in children and adolescents. *Pediatr Blood Cancer*. 2019;66:e27826.
- Devine KA, Mertens AC, Whitton JA, et al. Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: a report from the childhood cancer survivor study (CCSS). *Psychooncology*. 2018;27:613-619.
- Ness KK, Leisenring WM, Huang S, et al. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Cancer*. 2009;115:1984-1994.
- The Children's Oncology Group (COG). Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers (Version 5.0). The Children's Oncology Group (COG); 2018. http://www. survivorshipguidelines.org/pdf/2018/cog_ltfu_guidelines_v5.pdf
- 8. Moore SC, Lee I-M, Weiderpass E, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. *JAMA Intern Med.* 2016;176:816-825.
- Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet*. 2012;380:219-229.
- Casla S, Hojman P, Marquez-Rodas I, et al. Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. *Clin Transl Oncol.* 2015;17:180-196.
- Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32:335-346.
- 12. Braam KI, van der Torre P, Takken T, et al. Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. *Cochrane Database Syst Rev.* 2016;3:CD008796.
- Tillmann V, Darlington ASE, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. *J Bone Miner Res.* 2002;17:1073-1080.
- Odame I, Duckworth J, Talsma D, et al. Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood. *Pediatr Blood Cancer*. 2006;46:357-362.

- 15. Othman F, Guo CY, Webber C, Atkinson SA, Barr RD. Osteopenia in survivors of Wilms tumor. *Int J Oncol.* 2002;20:827-833.
- Sloof N, Hendershot E, Griffin M, Anderson L, Marjerrison S. The impact of physical activity on the health of young adult survivors of childhood cancer: an exploratory analysis. J Adolesc Young Adult Oncol. 2019;8:602-609.
- Warner JT, Evans WD, Webb DK, et al. Relative osteopenia after treatment for acute lymphoblastic leukemia. *Pediatr Res.* 1999;45: 544-551.
- Mogil RJ, Kaste SC, Ferry RJ Jr, et al. Effect of low-magnitude, highfrequency mechanical stimulation on BMD among young childhood cancer survivors: a randomized clinical trial. JAMA Oncol. 2016;2: 908-914.
- 19. Hartman A, te Winkel ML, van Beek RD, et al. A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2009;53:64-71.
- Rueegg CS, Kriemler S, Zuercher SJ, et al. A partially supervised physical activity program for adult and adolescent survivors of childhood cancer (SURfit): study design of a randomized controlled trial [NCT02730767]. BMC Cancer. 2017;17:822.
- Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer*. 2005;103: 1457-1467.
- 22. Michel G, von der Weid NX, Zwahlen M, et al. The Swiss Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. *Swiss Med Wkly*. 2007;137:502-509.
- Kelly TL, Wilson KE, Heymsfield SB. Dual energy x-ray absorptiometry body composition reference values from NHANES. *PLoS One*. 2009;4:e7038.
- 24. Troiano RP, Berrigan D, Dodd KW, et al. Physical activity in the United States measured by accelerometer. *Med Sci Sports Exerc.* 2008;40:181-188.
- Roggen I, Roelants M, Sioen I, et al. Pediatric reference values for tibial trabecular bone mineral density and bone geometry parameters using peripheral quantitative computed tomography. *Calcif Tissue Int*. 2015;96:527-533.
- R Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.
- 27. Zurcher SJ, Jung R, Monnerat S, et al. High impact physical activity and bone health of lower extremities in childhood cancer survivors: a cross-sectional study of SURfit. *Int J Cancer*. 2020;147:1845-1854.
- Vlok J, Simm PJ, Lycett K, et al. pQCT bone geometry and strength: population epidemiology and concordance in Australian children aged 11-12 years and their parents. *BMJ Open*. 2019;9:63-74.
- Vlachopoulos D, Barker AR, Ubago-Guisado E, et al. The effect of 12-month participation in osteogenic and non-osteogenic sports on bone development in adolescent male athletes. The PRO-BONE study. J Sci Med Sport. 2018;21:404-409.
- Gunter KB, Almstedt HC, Janz KF. Physical activity in childhood may be the key to optimizing lifespan skeletal health. *Exerc Sport Sci Rev.* 2012;40:13-21.
- 31. Robling AG, Turner CH. Mechanical signaling for bone modeling and remodeling. *Crit Rev Eukaryot Gene Expr.* 2009;19:319-338.
- Hart NH, Nimphius S, Rantalainen T, Ireland A, Siafarikas A, Newton RU. Mechanical basis of bone strength: influence of bone material, bone structure and muscle action. J Musculoskelet Neuronal Interact. 2017;17:114-139.
- 33. Suominen TH, Korhonen MT, Alen M, et al. Effects of a 20-week high-intensity strength and sprint training program on tibial bone structure and strength in middle-aged and older male sprint athletes: a randomized controlled trial. *Osteoporos Int.* 2017;28: 2663-2673.

- Daly RM, Ducher G, Hill B, et al. Effects of a specialist-led, school physical education program on bone mass, structure, and strength in primary school children: a 4-year cluster randomized controlled trial. *J Bone Miner Res.* 2016;31:289-298.
- Hughes JM, Gaffney-Stomberg E, Guerriere KI, et al. Changes in tibial bone microarchitecture in female recruits in response to 8 weeks of U.S. army basic combat training. *Bone*. 2018;113:9-16.
- Kampshoff CS, Jansen F, van Mechelen W, et al. Determinants of exercise adherence and maintenance among cancer survivors: a systematic review. Int J Behav Nutr Phys Act. 2014;11:80.
- Ness KK, Baker KS, Dengel DR, et al. Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2007;49: 975-981.
- Kuehl R, Schmidt ME, Dreger P, Steindorf K, Bohus M, Wiskemann J. Determinants of exercise adherence and contamination in a randomized controlled trial in cancer patients during and after allogeneic HCT. Support Care Cancer. 2016;24:4327-4337.
- Ormel HL, van der Schoot GGF, Sluiter WJ, Jalving M, Gietema JA, Walenkamp AME. Predictors of adherence to exercise interventions during and after cancer treatment: a systematic review. *Psychooncol*ogy. 2018;27:713-724.
- Cox CL, Zhu L, Kaste SC, et al. Modifying bone mineral density, physical function, and quality of life in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2018;65:e26929.

 Frotzler A, Coupaud S, Perret C, et al. High-volume FES-cycling partially reverses bone loss in people with chronic spinal cord injury. *Bone.* 2008;43:169-176.

INTERNATIONAL

JOURNAL of CANCER

- 42. Bauer JJ, Snow CM. What is the prescription for healthy bones? J Musculoskelet Neuronal Interact. 2003;3:352-355; discussion 356.
- Murphy NM, Carroll P. The effect of physical activity and its interaction with nutrition on bone health. *Proc Nutr Soc.* 2003;62:829-838.
- 44. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J Health Promot.* 1997;12:38-48.
- 45. Toh S, Hernan MA. Causal inference from longitudinal studies with baseline randomization. *Int J Biostat*. 2008;4:22.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Jung R, Zürcher SJ, Schindera C, et al. Effect of a physical activity intervention on lower body bone health in childhood cancer survivors: A randomized controlled trial (SURfit). *Int J Cancer*. 2023;152(2):162-171. doi:10.1002/ ijc.34234